Amisulpride in the Treatment of Schizophrenia

Česká verzia

Authors: L. Ustohal
Authors place of work: Psychiatrická klinika LF MU a FN Brno ; CEITEC MU, Brno
Published in the journal: Cesk Slov Neurol N 2011; 74/107(6): 706-708
Category: Treatment News

Summary

Amisulpride is a second generation D2 and D3 receptor blocking antipsychotic agent. It has so called biphasic affect – low doses increase and higher doses decrease dopaminergic neurotransmission. It has proven efficacy in the treatment of positive as well as negative symptoms of schizophrenia and, it is assumed that it also impacts on affective (depressive) symptoms and cognitive dysfunction. Amisulpride is effective as monotherapy although some evidence also exists of its efficacy when used in combinations, namely in combination with clozapine and, alternatively, olanzapine. It has only a few contraindications and, due to relatively low number of side-effects, is well-tolerated.

Key words:
amisulpride – schizophrenia – positive symptoms – negative symptoms

Zdroje

1. Češková E. Schizofrenie a její léčba. 2nd ed. Praha: Maxdorf 2007.

2. Švestka J. Nová psychofarmaka: Amisulprid – atypický preparát ve skupině antipsychotik 2. generace. Psychiatrie 2000; 3: 191–200.

3. Kopeček M. Amisulpridum. Remedia 2002; 12(3): 164–170.

4. Maitre M, Ratomponirina C, Gobaille S, Hode Y, Hechler V. Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics. Eur J Pharmacol 1994; 256(2): 211–214.

5. Češková E. Amisulprid – nové benzamidové antipsychotikum II. generace. Čes a slov Psychiat 2000; 96(8): 411–415.

6. Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H. Amisulpride: From animal pharmacology to therapeutic action. Int Clin Psychopharmacol 1997; 12 (Suppl 2): 29–36.

7. Barik S, de Beaurepaire R. Evidence for a functional role of the dopamine D3 receptors in the cerebellum. Brain Res 1996; 737(1–2): 347–350.

8. Mortimer AM. Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr Dis Treat 2009; 5: 267–277.

9. Danion J, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 1999; 156(4): 610–616.

10. Moller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol. Psychopharmacol 1997; 132(4): 396–401.

11. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual „atypical“ antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159(2): 180–190.

12. Češková E. Deniban v léčbě dystymie. Čes a slov Psychiat 2007; 103(2): 73–79.

13. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 2002; 17(1): 1–13.

14. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci 2004; 114(6): 593–611.

15. Wagner M, Quednow BB, Westeide J, Schlaepfer TE, Maier W, Kuhn KU. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacol 2005; 30(2): 381–390.

16. Mortimer AM, Joyce E, Balasubramaniam D, Choudhary PC, Saleem PT. Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. Hum Psychopharmacol 2007; 22(7): 445–454.

17. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60(6): 553–564.

18. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; 1: CD006624.

19. Molina JD, Toledo-Romero F, López-Rodriguez E, Amorin-Díaz M, Lerma-Carrillo I, López-Munoz F. Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine. Pharmacopsychiatry 2011; 44(4): 142–147.

20. Ziegenbein M, Sieberer M, Kuenzel H, Kropp S. Augmentation of clozapine with amisulpride in patients with treatment-resistant schizophrenia: an open label clinical study. Ger J Psychiatry 2006; 9(1): 17–21.

21. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008; 41(1): 24–28.

22. Genc Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 2007; 24(1): 1–13.

23. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol 2006; 21(2): 99–103.

24. Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: a review of treatment strategies. Can J Psychiatry 2007; 52(6): 377–384.

25. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2010. Dostupné z URL: http://schizophreniabulletin.oxfordjournals.org/content/early/2010/05/30/schbul.sbq042.full

26. McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18(13): 933–956.

27. Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14(4): 209–218.

28. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123(2–3): 225–233.

29. Prikryl R, Ustohal L, Prikrylova-Kucerova H. Amisulpride therapeutic dose-induced asymptomatic bradycardia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(1): 290.

30. Riedel M, Eich FX, Moller HJ. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. Eur Psychiatry 2009; 24(3): 149–153.